Acadia Pharmaceuticals Q3 Revenue Rises 23% on DAYBUE, NUPLAZID Sales
Acadia Pharmaceuticals reported a 23% rise in third-quarter revenue, citing DAYBUE and NUPLAZID sales.
Acadia Pharmaceuticals reported a 23% rise in third-quarter revenue, citing DAYBUE and NUPLAZID sales.